News for DexCom, Inc. (DXCM.MX)

DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Click here to read an analysis of DXCM stock now.

Dexcom's growth in sensors and U.S. expansion is solid, but slowing revenue growth and high valuation limit upside. Click here to read my most recent analysis.

The FDA has issued a recall for some Dexcom glucose monitors due to a speaker defect. Analysts forecast a potential 19.24% upside for Dexcom within the

[url=

DexCom Inc. (DXCM) unveils the Season 4 roster for its innovative Name, Image, and Likeness (NIL) program, welcoming 13 new athletes with diabetes. The

On July 16, 2025, Mizuho analyst Anthony Petrone issued a report on DexCom (DXCM), maintaining an "Outperform" rating and raising the price target from $95.00 t

Mizuho analyst Anthony Petrone has increased the price target for DexCom (DXCM) from $95 to $100, while maintaining an Outperform rating. This adjustment comes

Morgan Stanley has updated its price target for DexCom (DXCM), one of the leaders in glucose monitoring technology. The new price target set by analyst Patrick

Summary On July 15, 2025, DexCom Inc (DXCM), a leader in glucose biosensing, released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United

PR NewswireNEW YORK, July 15, 2025 MarketNewsUpdates News CommentaryNEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are rev

Morgan Stanley, through analyst Patrick Wood, has adjusted the price target for DexCom (DXCM), raising it from $82 to $89. Despite maintaining an Equal Weight r

Below is the June 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board member

DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.

Highest volume of listings and capital raise in the first half of the year since 2021

DexCom, Inc. (NASDAQ:DXCM) ranks among the best fundamental stocks to buy according to hedge funds. Oppenheimer reaffirmed its $95 price target and Outperform rating for DexCom, Inc. (NASDAQ:DXCM) on June 24 in response to remarks made by Health and Human Services Secretary RFK Jr. regarding a significant wearables campaign. At a June 24 hearing of […]

DexCom (DXCM) leads the S&P 500 healthcare sector with a weekly surge of 7.92%, outperforming rivals. Analysts set a one-year average price target for D

In the current session, DexCom Inc. DXCM is trading at $86.18, after a 1.59% decrease. Over the past month, the stock decreased by 0.92%, and in the past year, ...

Summary DexCom Inc (DXCM), a leader in glucose biosensing technology, has released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United St